EXCITE clinical trial data reported at NCVH demonstrates acute, superior procedural success

Published on:

A presentation by principal investigator Eric J. Dippel, MD, of Genesis Heart Institute in Davenport, Iowa, at the annual New Cardiovascular Horizons (NCVH) conference in New Orleans last week demonstrated significant procedural advantage of laser atherectomy in the largest randomized trial of atherectomy ever conducted.

The EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis (EXCITE ISR) showed a 93.5% procedural success rate with laser atherectomy plus PTA (also known as balloon angioplasty) for the treatment of ISR versus 82.7% with PTA alone.

These findings, which are confirmed by an independent core lab and currently under FDA review, represent the first randomized, multi-center clinical trial results demonstrating the benefits of atherectomy in ISR. Study results also show a lower major dissection rate (2.4% vs. 7.4% with PTA alone) and additional stenting (4.7% vs. 13.6% with PTA alone).

According to Amanda Johnson, Vice President of Regulatory and Medical Affairs for The Spectranetics Corporation, which sponsored the study, "It is remarkable to see these superior clinical outcomes, affirming the exceptional performance of laser atherectomy. This is critical to elevating the current standard of care for patients suffering from peripheral artery disease (PAD). The findings generate new insights and more complete evidence to enable physicians to determine which treatment options are best for their patients."

"Notably, the average lesion length was nearly 20 cm in both arms, indicative that this was a true real- world study as opposed to some of the stent IDE studies with average lesion lengths of four to six cm,"
Dr. Dippel pointed out. "In addition, approximately three times as many patients in the laser arm presented with severe calcification as compared to the angioplasty arm."

In-stent restenosis (ISR) occurs when a previously placed stent becomes occluded, or blocked, and is considered to be a challenging condition to treat. Spectranetics designed this treatment-to-control trial to show safety and efficacy of treatment with laser atherectomy in patients with ISR.

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."